SS Innovations International Inc. (NASDAQ: SSII) is expanding its presence in the global surgical robotics market through its proprietary SSi Mantra robotic surgery platform, according to a recent announcement. The company’s strategy combines world-class robotic systems, including telesurgery capabilities, with affordability, physician training, and international market expansion.
More than 200 SSi Mantra systems have been installed worldwide, supporting over 12,000 robotic procedures across more than 170 surgical indications. This installed base positions the company as a growing player in the fast-evolving market for robotic-assisted surgery, where healthcare systems increasingly seek technologies that improve surgical precision while expanding patient access.
Unlike many developers focused primarily on premium hospital systems, SS Innovations has concentrated on reducing the economic barriers that have limited adoption of robotic surgery in many regions. The company believes lowering acquisition and operating costs can allow more hospitals to introduce robotic-assisted procedures without sacrificing advanced capabilities. This approach could have significant implications for patients and healthcare providers globally, as it may broaden access to minimally invasive surgery—a key trend driving demand in the industry.
SS Innovations continues pursuing U.S. FDA clearance and European regulatory approvals while building its installed base internationally. Obtaining these approvals would mark a critical milestone, potentially opening large markets in North America and Europe. For readers, this means that the SSi Mantra system could become available in more hospitals, offering an alternative to existing robotic platforms that are often costly and limited to major medical centers.
The growing demand for minimally invasive surgery and broader access to robotic procedures continues to create opportunities for emerging high-tech medical technology companies like SS Innovations. With over 12,000 procedures already performed, the company is demonstrating real-world clinical use, which may help build confidence among surgeons and hospital administrators considering adoption.
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. InvestorWire, a specialized communications platform, distributed this press release as part of its services for private and public companies. More information about InvestorWire can be found at https://www.InvestorWire.com.
